BlackRock
EFTR

BlackRock’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

BlackRock’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22
Closed -$259 – 5421
2023
Q4 		$259 Hold
22
– – ﹤0.01% 5309
2023
Q3 		$332 Hold
22
– – ﹤0.01% 5366
2023
Q2 		$460 Sell
22
-2,101
-99% -$35.5K ﹤0.01% 5429
2023
Q1 		$18.7K Buy
2,123
+732
+53% +$8.88K ﹤0.01% 5261
2022
Q4 		$14.9K Buy
1,391
+111
+9% +$1.41K ﹤0.01% 5410
2022
Q3 		$18K Buy
1,280
+612
+92% +$12K ﹤0.01% 5531
2022
Q2 		$24K Buy
668
+623
+1,384% +$37.7K ﹤0.01% 5533
2022
Q1 		$4K Hold
45
– – ﹤0.01% 5700
2021
Q4 		$10K Buy
+45
New +$10.4K ﹤0.01% 5607

Other funds holding EFTR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BlackRock's EFTR Position: Q1 2024 in Review

BlackRock sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 22 shares — an estimated $259 sold.

BlackRock first reported a position in EFTR in Q4 2021 and held it in 9 quarters. The position peaked at $24K in Q2 2022. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

  • BlackRock reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 22 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $259.
  • BlackRock first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • BlackRock's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $24K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.